<DOC>
	<DOC>NCT02511561</DOC>
	<brief_summary>This is a 1-month, multicenter, open-label study in subjects with unilateral otitis externa. Eligible subjects will receive a single dose of 6 mg OTO-201 to the affected ear. The study is designed to characterize safety, procedural factors and clinical effect of OTO-201 administered in subjects with otitis externa.</brief_summary>
	<brief_title>OTO-201 for the Treatment of Otitis Externa</brief_title>
	<detailed_description />
	<mesh_term>Otitis</mesh_term>
	<mesh_term>Otitis Externa</mesh_term>
	<mesh_term>Ciprofloxacin</mesh_term>
	<criteria>Inclusion Criteria includes, but is not limited to: Subject is a male or female aged 6 months to 80 years, inclusive Subject has a clinical diagnosis of unilateral otitis externa Subject or subject's caregiver is willing to comply with the protocol and attend all study visits Exclusion Criteria includes, but is not limited to: Subject has tympanic membrane perforation Subject has a history of known immunodeficiency disease Subject has fungal otitis externa, based on clinical signs</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Otitis externa</keyword>
	<keyword>Swimmer's ear</keyword>
	<keyword>Ear infection</keyword>
</DOC>